Comprehensive Pain Management in Oncology: A Multidisciplinary Approach - Tumor Boards

Comprehensive Pain Management in Oncology: A Multidisciplinary Approach - Tumor Boars is a four-part educational series designed to equip oncology healthcare professionals with the knowledge and skills needed to assess, manage, and monitor cancer-related pain using evidence-based, patient-centered approaches. Through a combination of foundational education, practical management strategies, and complex case-based discussions, learners will build competence in pain assessment, multimodal treatment planning, the safe and effective use of opioid analgesics, and the management of patients with coexisting substance use disorders. The series emphasizes interprofessional collaboration, functional outcomes, risk mitigation, and appropriate referral strategies to support comprehensive, high-quality cancer pain care across the continuum of oncology practice.

Provided by National Comprehensive Cancer Network in collaboration with The France Foundation.

Target Audience

The primary audience who will benefit from this education includes physicians, physician associates, nurse practitioners, pharmacists, nurses, social workers, and other health care professionals involved in the care of adult patients with cancer pain.

Learning Objectives

Following this program, participants should be able to:

Module 1

Explain core principles and mechanisms of cancer-related pain and its management
Conduct evidence-based assessments of pain in patients with cancer, that evaluate functional impact and screen for OUD risk factors

Module 2

Implement individualized pharmacologic and non-pharmacologic strategies tailored to pain type, function, and patient goals
Integrate opioid analgesics into a comprehensive cancer pain plan when appropriate
Appraise the efficacy of analgesics based on objective functional outcomes and patient-reported relief

Module 3

Execute the safe initiation, titration, monitoring, and discontinuation of opioid therapies
Counsel patients and caregivers on safe opioid storage and disposal, and the emergency use of naloxone

Module 4

Identify foundational concepts of addiction medicine and their intersection with oncology
Develop management strategies for patients with cancer who have a comorbid OUD
Determine appropriate indications for referral to pain, palliative care, or addiction specialists

Additional information

Supporters:

This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies.

Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements that are issued by the US Food and Drug Administration (FDA).

Course summary

Course opens:

10/30/2026

Course expires:

10/29/2027

FACULTY

David S. Craig, PharmD
Advanced Practice Pharmacist
Acute Pain and Supportive Care Medicine
Moffitt Cancer Center
Tampa, FL

Megan R. Prescott, LCSW, ASWPH-C
Lead Palliative Care Social Worker
University of Colorado Hospital
Aurora, CO

Elizabeth Horn Prsic, MD
Associate Professor, Section of Medical Oncology & Hematology
Yale University
New Haven, CT

Carey Ramirez, DNP, ANP-C, ACHPN
Director, Advanced Practice Department
Supportive Care Medicine
City of Hope
Duarte, CA

Jessica Vanderlan, PhD
Clinical Psychologist
Clinical Assistant Professor, Psychiatry
Siteman Cancer Center
BJH & Washington University School of Medicine
St. Louis, MO

Jeanie Youngwerth, MD, FAAHPM
Associate Professor of Medicine
Associate Program Director
Colorado Palliative Medicine Fellowship
Director, Palliative Care Service
University of Colorado - Anschutz
Aurora, CO

PEER REVIEWER

Nicholas Burwick, MD
Academic Associate Professor
Division of Hematology and Oncology
University of Washington
VA Puget Sound Health Care System
Seattle, WA

NCCN CONTINUING EDUCATION DISCLOSURE POLICY

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

FACULTY DISCLOSURES

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Carey Ramirez, DNP, ANP-C, ACHPN
Jessica Vanderlan, PhD
Jeanie Youngwerth, MD, FAAHPM

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Nicholas Burwick, MD
Bristol Myers Squibb: Speaker’s Bureau
Takeda: Speaker’s Bureau

David S. Craig, PharmD
Patient Centered Outcome Research Institute (PCORI): Research

Megan R. Prescott, LCSW, ASWPH-C
Boehringer-Ingelheim (Obesity): Consultant; Speaker’s Bureau
Eli Lilly (Obesity): Speaker’s Bureau
Novo Nordisk (Obesity): Speaker’s Bureau

Elizabeth Horn Prsic, MD
Luminate Medical: Consultant

NCCN AND THE FRANCE FOUNDATION DISCLOSURES

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

DISCLOSURE OF UNLABELED USE

Faculty for this educational activity are required to disclose when a therapy or procedure being discussed is off-label, unlabeled, experimental, or investigational, and to note any limitations of the data presented (e.g., preliminary findings, ongoing research, or expert opinion).

Some faculty may discuss uses of pharmaceutical agents or devices that are not included in U.S. Food and Drug Administration–approved labeling. These discussions are provided solely for educational purposes and should not be construed as a recommendation for any particular use. Learners are encouraged to review full prescribing information for products discussed.

DISCLAIMER

This activity is intended for healthcare professionals for educational purposes only. The content reflects information available at the time of development and may not represent the most current evidence, regulatory status, or prescribing information. Participants should consult current package inserts, clinical guidelines, and institutional policies before prescribing medications or making clinical decisions.

This activity has been planned and implemented in compliance with applicable accreditation standards to ensure that content is fair, balanced, evidence-based, and free of commercial bias.

AI-ASSISTED CONTENT

This educational activity includes content generated with the support of artificial intelligence (AI)/chatbot tools and reviewed by subject-matter experts. It is intended solely for educational purposes and does not provide medical advice, diagnosis, or treatment recommendations.

AI supported content may contain errors or omissions, and it should not be relied upon as a substitute for the independent clinical judgment of qualified healthcare professionals or for patient specific decision making.

Learners are responsible for critically evaluating all information and applying it in accordance with professional standards, current evidence, regulatory requirements, and the laws of their practicing jurisdiction.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

PHYSICIANS
NCCN designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES
NCCN designates this activity for a maximum of 4.0 contact hours.

PHYSICIAN ASSOCIATES
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 4.0 AAPA Category 1 CME credits. Approval is valid until October 29, 2027. PAs should only claim credit commensurate with the extent of their participation.

PHARMACISTS

NCCN designates this knowledge-based continuing education activity for 4.0 contact hours (0.40 CEUs) of continuing pharmacy education credit.

UAN Module 1: JA4008196-0000-26-072-H08-P

UAN Module 2: JA4008196-0000-26-106-H08-P

UAN Module 3: JA4008196-0000-26-107-H08-P

UAN Module 4: JA4008196-0000-26-108-H08-P

Upon successfully completing the evaluation, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

SOCIAL WORKERS

As a Jointly Accredited Organization, NCCN is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. NCCN maintains responsibility for this course. Social workers completing this course receive 4.0 continuing education credits.

All other healthcare professionals completing this course will be issued a statement of participation.

Completion of all 4 modules is required for REMS compliance.

Status

Price

Title

Locked

$0.00Included

Comprehensive Pain Management in Oncology: A Multidisciplinary Approach - Tumor Boards